Cargando…

Suppression of p16 Induces mTORC1-Mediated Nucleotide Metabolic Reprogramming

Reprogrammed metabolism and cell cycle dysregulation are two cancer hallmarks. p16 is a cell cycle inhibitor and tumor suppressor that is upregulated during oncogene-induced senescence (OIS). Loss of p16 allows for uninhibited cell cycle progression, bypass of OIS, and tumorigenesis. Whether p16 los...

Descripción completa

Detalles Bibliográficos
Autores principales: Buj, Raquel, Chen, Chi-Wei, Dahl, Erika S., Leon, Kelly E., Kuskovsky, Rostislav, Maglakelidze, Natella, Navaratnarajah, Maithili, Zhang, Gao, Doan, Mary T., Jiang, Helen, Zaleski, Michael, Kutzler, Lydia, Lacko, Holly, Lu, Yiling, Mills, Gordon B., Gowda, Raghavendra, Robertson, Gavin P., Warrick, Joshua I., Herlyn, Meenhard, Imamura, Yuka, Kimball, Scot R., DeGraff, David J., Snyder, Nathaniel W., Aird, Katherine M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6716532/
https://www.ncbi.nlm.nih.gov/pubmed/31433975
http://dx.doi.org/10.1016/j.celrep.2019.07.084
Descripción
Sumario:Reprogrammed metabolism and cell cycle dysregulation are two cancer hallmarks. p16 is a cell cycle inhibitor and tumor suppressor that is upregulated during oncogene-induced senescence (OIS). Loss of p16 allows for uninhibited cell cycle progression, bypass of OIS, and tumorigenesis. Whether p16 loss affects pro-tumorigenic metabolism is unclear. We report that suppression of p16 plays a central role in reprogramming metabolism by increasing nucleotide synthesis. This occurs by activation of mTORC1 signaling, which directly mediates increased translation of the mRNA encoding ribose-5-phosphate isomerase A (RPIA), a pentose phosphate pathway enzyme. p16 loss correlates with activation of the mTORC1-RPIA axis in multiple cancer types. Suppression of RPIA inhibits proliferation only in p16-low cells by inducing senescence both in vitro and in vivo. These data reveal the molecular basis whereby p16 loss modulates pro-tumorigenic metabolism through mTORC1-mediated upregulation of nucleotide synthesis and reveals a metabolic vulnerability of p16-null cancer cells.